Pendulum Therapeutics
San Francisco
About Pendulum Therapeutics
Pendulum Therapeutics believes therapies developed using evidence-based microbiome science and DNA sequencing can help heal the body from within. Armed with 13 patents and 42 pending, the company introduced its flagship product Pendulum Glucose Control, a medical probiotic, in 2020 and demonstrated its efficacy in lowering blood sugar spikes and reducing A1C in a published clinical trial. Founded in 2013 by a diverse team of scientists with deep microbiology, biochemistry, computational, and clinical expertise, Pendulum has raised $111 million to date from Meritech Capital, Sequoia Capital, True Ventures, Khosla Ventures, AME Cloud Ventures and Mayo Clinic among others. Pendulum Therapeutics is headquartered in San Francisco.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $121.2M
- Funding stage: Late Stage Venture
- Last round: Series C (Feb 2024)
- Website: pendulumlife.com
- Phone: 844-912-2256
Industries & Categories
Biotechnology, Health Care, Health Diagnostics, Medical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/pendulum-therapeutics-23647 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.